Using the Immune System to Improve the Efficacy of Radiation Therapy

Using the Immune System to Improve the Efficacy of Radiation Therapy
Using the Immune System to Improve the Efficacy of Radiation Therapy

Researchers have discovered a key mechanism by which radiotherapy fails to completely destroy tumors. In a study involving a mouse model described in Nature Immunology (doi:10.1038/ni.3270), the investigators offer a novel solution to promote successful radiotherapy for the millions of cancer patients who receive this treatment.

Researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai in New York City found that when radiotherapy damages skin harboring tumors, Langerhans cells are activated. These immune cells can repair the damage in their own DNA caused by radiotherapy, allowing them to become resistant to radiotherapy and to even trigger an immune response causing skin tumors such as melanoma to resist further treatment.

Investigators mimicked the effect of immune checkpoint inhibitors to boost the immune system to attack tumors. This in turn blocked the ability of Langerhans cells to repair their own DNA after radiotherapy, causing them to die.

“Our study suggests that this combination approach, combining radiotherapy with drugs that rev up a healthy immune response, will help make radiation therapy much more effective,” said the study's lead author, immunologist Jeremy Price, PhD.

While this study was conducted using mouse models of melanoma and focused on the skin where Langerhans cells are located, the researchers believe the same process happens in organs throughout the body. Dendritic cells are also activated by radiotherapy, and the investigators stressed that it is critical we understand how they respond to treatment as well.

“Similarly, checkpoint-inhibiting drugs have revolutionized the treatment of melanoma and are being investigated in many other cancers,” said co-author Miriam Merad, MD, PhD, Professor of Tumor Immunology, Oncological Sciences, and Hematology and Medical Oncology at The Tisch Cancer Institute.

“Cancer has the ability to turn off and even evade the body's natural immune response to tumors. The new immunotherapy drugs take the brakes off the immune system, promoting a powerful and complete immune response to the cancer.”

“This is synergized by the addition of radiation, which can expose the tumor so it can better be targeted by the immune system,” said Dr Price. “By combining these treatments, the ability of Langerhans cells to use the immune system to protect cancers will be overwhelmed.”

Ionizing radiation is a powerful therapeutic tool that causes toxic breaks in cellular DNA. The formation of these breaks triggers a response in Langerhans cells, which are usually dormant, to stop further damage and to repair the breaks. The researchers discovered that when the skin is damaged by ionizing radiation, Langerhans cells travel to nearby lymph nodes to communicate with other immune cells and help program a population of regulatory T cells that dampen the immune system. These regulatory T cells then travel back to the damaged tumor and shield it from attack by the immune system.

“We found melanoma grew much more quickly on mice pretreated with radiation compared to untreated mice because of the presence of regulatory T cells activated by Langerhans cells,” Dr Price said. “These Langerhans cells were resistant to radiation.”

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs